NCT Number: NCT04140526
Phase: Phase 1|Phase 2
Trial Summary: This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single a – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym: PRESERVE-001
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives